Cargando…

MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells

Combination therapy of erlotinib plus bevacizumab improves progression-free survival of patients with epidermal growth factor receptor–mutated (EGFR-mutated) advanced non–small-cell lung cancer (NSCLC) compared with erlotinib alone. Although improved delivery and distribution of erlotinib to tumours...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishidate, Masanobu, Yamamoto, Kaname, Masuda, Chinami, Aikawa, Hiroaki, Hayashi, Mitsuhiro, Kawanishi, Takehiko, Hamada, Akinobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711937/ https://www.ncbi.nlm.nih.gov/pubmed/29196706 http://dx.doi.org/10.1038/s41598-017-17211-6

Ejemplares similares

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging
por: Aikawa, Hiroaki, et al.
Publicado: (2016)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
por: Nishimura, Meiko, et al.
Publicado: (2018)

Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging
por: Tsubata, Yukari, et al.
Publicado: (2017)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
por: Li, Heyan, et al.
Publicado: (2014)

Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model
por: Ishikura, Nobuyuki, et al.
Publicado: (2019)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Erlotinib Inhibits Growth of a Patient-Derived Chordoma Xenograft
por: Siu, I-Mei, et al.
Publicado: (2013)

Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
por: Masuda, Chinami, et al.
Publicado: (2019)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
por: Iwai, Toshiki, et al.
Publicado: (2016)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

Erlotinib and Concurrent Chemoradiation in Pretreated NSCLC Patients: Radiobiological Basis and Clinical Results
por: Ramella, Sara, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo, Alessia E, et al.
Publicado: (2017)

Report of the use of patient‐derived xenograft models in the development of anticancer drugs in Japan
por: Tsumura, Ryo, et al.
Publicado: (2020)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

CompTIA A+ 220-901 and 220-902
por: Prowse, David L
Publicado: (2016)

Hemilaminectomy for the removal of the spinal tumors: An analysis of 901 patients
por: Liao, Dengyong, et al.
Publicado: (2023)

Cutaneous Leukocytoclastic Vasculitis Associated with Erlotinib
por: Sawada, Takahiro, et al.
Publicado: (2016)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC
por: Krentz Gober, Madeline, et al.
Publicado: (2017)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Structure and Assembly of TP901-1 Virion Unveiled by Mutagenesis
por: Stockdale, Stephen R., et al.
Publicado: (2015)

Clear Plaque Mutants of Lactococcal Phage TP901-1
por: Kot, Witold, et al.
Publicado: (2016)

Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts
por: Liao, Ming-juan, et al.
Publicado: (2014)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
por: Kuiper, J L, et al.
Publicado: (2012)

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9ddqtffm843396ui1dubn1186t